All News

RheumNow Podcast square

EULAR 2022 Top 10 Abstracts (6.10.2022)

Jack Cush, MD

Dr. Jack Cush reviews the top abstracts from EULAR 2022  As chosen by me with the  aid of the RheumNow EULAR faculty.

Read Article
computer screen safety

The Safety of Rituximab and JAK Inhibitors with post-COVID Vaccination

Md Yuzaiful Md Yusof, MRCP(UK), PhD

At the onset of the pandemic, data from the Global Rheumatology Alliance reported increased risk of poor severe COVID outcomes including deaths in patients who were treated with rituximab and baricitinib. With the vaccination program undertaken globally, has this risk been attenuated?

Read Article
Malar,rash,SLE, Lupus

Emerging Therapeutics for Lupus

Kathryn H. Dao, M.D.

Impressive data on novel treatment for SLE were presented at the EULAR22 Congress. A disease that is difficult to study due to its pleomorphic presentation, unpredictable disease course, and high mortality rates, SLE is considered the dragon of all autoimmune diseases. Here are highlights of four exciting abstracts presented at the meeting with emerging therapeutics designed to slay the beast. 

Read Article
exhibitor.floor.ACR

EULAR 2022 – Day 4 Report

Jack Cush, MD

Bags are packed, ready to go, but wait there’s more abstracts to show.



The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased. 

Read Article
ice cubes

Topical therapies take centre stage

Richard Conway, MBBChBAO, PhD

Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. 

Read Article
AVOID THE WEEKEND! Study of high-impact rheumatology journals (Rheumatology, J Rheum, & Seminars A&R) shows higher risk of "desk rejections" by editor (avoiding peer review) for manuscripts submitted Saturday (OR 1.23) or Sunday (OR 1.13) https://t.co/8LAymRZBth https://t.co/g5koHHZZaX

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Let’s Talk about Sex and Autoimmune Disease Dr. Eric Dein discusses abstract OP0139 presented at #EULAR2022. https://t.co/fNcIbykFqL https://t.co/6UaH5DIc51

Links:

Dr. John Cush RheumNow ( View Tweet)
Topical therapies take centre stage Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. #EULAR2022 https://t.co/V9plk1vAEd https://t.co/fyNWWtconi

Links:

Dr. John Cush RheumNow ( View Tweet)
🆒 Couldn't attend my #EULAR2022 talk about the role of #twitter in #Rheumatology? Check the 2 slides below summarizing the role of #socialmedia for the dissemination of medical information. #TwitterRheum ⬇️ BEFORE vs AFTER Twitter ⬇️ https://t.co/ZzVdoWYEMr
Laurent ARNAUD Lupusreference ( View Tweet)
Watch: #EULAR2022 - Day 4 Faculty Panel Recap Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006. https://t.co/B7AYkTnAe0 https://t.co/NF3f6AFv6K

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2022 – Day 4 Report Check out our my favorite late-breakers from Day 4. https://t.co/R0hPetOos4 https://t.co/T57XRIKZs5

Links:

Dr. John Cush RheumNow ( View Tweet)
WATCH: #EULAR2022 - Day 3 Faculty Panel Recap Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022. https://t.co/ExCXY6Xbl4 @Janetbirdope @AurelieRheumo @Yuz6Yusof https://t.co/tIB8QrdYuI

Links:

Dr. John Cush RheumNow ( View Tweet)
MIVAC I & II RCTs from India: for AZ vaccine (ChAdOx1), withhold MTX for 2w after: hold both dose 1&2 or hold just dose 2 (vs continue) Endpoint: Ab titre both hold approaches better than continue, to a similar magnitude - similar to German study w mRNA #EULAR2022 @RheumNow

David Liew drdavidliew ( View Tweet)

#LB0006 #EULAR2022 Therapy for relapsing polymyalgia rheumatica. 118/280 recruited re:COVID impact. Phase 3 RCT of Sarilumab+14Wk Steroid taper showed more pts had sustained remission at Wk52 vs PBO+52Wk Steroid Taper(28% vs 10%) even if CRP excluded. PRO improved too! @RheumNow https://t.co/P11iXIAfGn
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Novel ePROMS use. Use of ePROMS RAPID3/PASS and asking patients if they had a flare had high diagnostic accuracy identifying those not needing DMARD or steroid intensification up and eligible to skip their next outpatient clinic visit. Seppen et al #EULAR2022 @RheumNow POS0381

Dr. Antoni Chan synovialjoints ( View Tweet)

Who remotely enters PROs online? Glintborg et al from the Danbio Registry showed that patients who used the system were mainly 40-80 years of age, on biologics and had lower HAQ score. Disease duration and diagnosis had no impact, reminders helped #EULAR2022 @RheumNow POS0373 https://t.co/voCfGiJgwm
Dr. Antoni Chan synovialjoints ( View Tweet)
#POS1112 #EULAR2022 A crossover RCT assessed effect of weight- and non-weight bearing exercises on type 2 collagen in knee #osteoarthritis. Small rise in collagen turnover markers initially for 24hrs. Gradual rise later on was contributed to cardiovascular influence @RheumNow https://t.co/AOxdFNihPR
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The potential for patients to benefit from digital health technologies in rheumatology is multifaceted, upside might be enormous. There's so much space for us all, but there are factors in many domains where it can all go wrong. We need to raise standards. #EULAR2022 @RheumNow https://t.co/TozfK1Qs16
David Liew drdavidliew ( View Tweet)
Agree. Love to understand: - standardisation for whole body MRI - how it does not compromise image quality vs limited field - clear explanation of benefit vs limited field, where it exists Its inappropriate use in the worried well by charlatans has skewed me #EULAR2022 @RheumNow https://t.co/3LRz0OOAEF

Links:

David Liew drdavidliew ( View Tweet)

Sousa et al. Anti-Ku disease. Cluster analysis (Ku alone, Ku with other abs) asking is is a distinct entity. In isolated anti-Ku+ maybe so, characterised by Raynauds (41%), arthritis (26%), sicca (26%), myositis (15%), ILD (15%) @RheumNow #EULAR2022 POS0861 https://t.co/IboWzMYFMB
Richard Conway RichardPAConway ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×